Canine & Feline Joint Program — Clinic-Administered EV Mobility Course for Senior Pets

The problem this playbook solves: pet joint care is thin files or surgery — a clinic-administered EV program with characterized material and veterinary protocols is the missing middle.

01 · The problem

Companion-animal joint care offers two ends: daily supplements with thin documentation, or surgical intervention. The clinic-administered middle — a characterized EV mobility course, protocol-guided, for stiff senior pets — is the program Gallant-style operators proved in the US regulatory pathway and most markets still lack. TONGNIAN's version enters through veterinary channels with documentation-first discipline.

02 · Scientific rationale

MSC-EV intra-articular administration is supported by the osteoarthritis literature (immunomodulatory and chondroprotective-associated signalling in models and early clinical work) [3]. The pet program adapts the same administration logic for pets: characterized batches, veterinary protocols, clinic session records. characterized batches, veterinary protocols, and clinic session records — the same material chain as the human lines, adapted per market's veterinary rules.

03 · Program documentation

Joint-program session structures follow TONGNIAN's internal veterinary-protocol documentation; companion-animal market landscape research (2026-08) informs the entry sequencing [4]. [6]

Method anchors: [1] EV biology and cargo [2] MISEV2018 characterization [3] category evidence (review or registered study) [4] formulation and handling guidance [5] national measurement guideline (2026 No. 17) [6] internal protocol and case documentation.

04 · Product architecture

05 · Process & QC

EV material runs on the fully enclosed 0.5–5 L micro-batch line with low-shear handling qualified at process validation [4]. QC panel design follows MISEV2018 [2] and the national measurement guideline (2026 No. 17, TONGNIAN a drafting organization) [5].

Fig. 1 — The clinic entry sequence: flagship course → continuation → platform.

06 · Regulatory pathway: EU & US first

Professional-use positioning: clinic or veterinary channel only, with protocol and training materials included. Material chain (DMF Type II 044197, INCI 41316) documented; finished programs follow destination-market professional-use rules. No consumer therapeutic claims — clinic education carries the message; the veterinary route follows each destination market's rules.

07 · Expected outcomes

• Flagship-first entry: land one program per clinic and prove the reorder pattern in session records before offering the wider platform.
• Documentation-first trust: characterized batches and session records open the vet door.
• Category whitespace: veterinary EV programs are an early, open category.

Wording stays inside each destination market's rules; batch measurement does the persuading.

08 · Commercial framework

Sample kits in 3–5 days; pilot from 500 units; production from 2,000 units; standard lead 15 workdays — all indicative, quoted per request. White-label runs through the OBM program.

Request a quote · Line fact-sheet

References

1. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.
2. Engineering of MSC-derived exosomes: a promising cell-free therapy for osteoarthritis. PMC9413347.
3. Théry C, et al. MISEV2018. J Extracell Vesicles. 2018;7(1):1535750.
4. Companion-animal regenerative market landscape — TONGNIAN desk research, 2026-08.
5. TONGNIAN network clinics. Anonymized internal protocol and case documentation (partner access under NDA).